Drug Profile
Eluvixtamab - Amgen
Alternative Names: AMG-330Latest Information Update: 17 Jun 2022
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; BeiGene
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 31 May 2022 Amgen terminates phase I trial in Acute myeloid leukemia in the US, Canada, Germany and Netherlands due to prioritization decision (NCT02520427)
- 04 May 2022 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV) (Amgen pipeline, May 2022)
- 04 May 2022 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in Netherlands, Germany, Canada, USA (IV) (Amgen pipeline, May 2022)